Cargando…

Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy

OBJECTIVE: This study aimed to deliver a polypeptide from the Bax-BH3 domain (BHP) through the synthesis of self-assembled amphiphile nanovectors (NVs) and to assess their potential for cancer therapeutic applications and biological safety in vitro and in vivo. These findings provide valuable option...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Zhang, Mingming, Huang, Sijun, Ohtani, Kiyoshi, Xu, Li, Guo, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517702/
https://www.ncbi.nlm.nih.gov/pubmed/37746048
http://dx.doi.org/10.2147/IJN.S427536
_version_ 1785109378579300352
author Zhang, Xi
Zhang, Mingming
Huang, Sijun
Ohtani, Kiyoshi
Xu, Li
Guo, Yi
author_facet Zhang, Xi
Zhang, Mingming
Huang, Sijun
Ohtani, Kiyoshi
Xu, Li
Guo, Yi
author_sort Zhang, Xi
collection PubMed
description OBJECTIVE: This study aimed to deliver a polypeptide from the Bax-BH3 domain (BHP) through the synthesis of self-assembled amphiphile nanovectors (NVs) and to assess their potential for cancer therapeutic applications and biological safety in vitro and in vivo. These findings provide valuable options for cancer intervention and a novel approach for the rational design of therapeutics. METHODS: We studied the antitumor activity of BHP by preparing RGDfK-PHPMA-b-Poly (MMA-alt-(Rhob-MA)) (RPPMMRA) and encapsulating it in BHP-NV. We also performed a series of characterizations and property analyses of RPPMMRA, including its size, stability, and drug-carrying capacity. The biocompatibility of RPPMMRA was evaluated in terms of cytotoxicity and hemolytic effects. The pro-apoptotic capacity of BHP was evaluated in vitro using mitochondrial membrane potential, flow cytometry, and apoptosis visualization techniques. The potential therapeutic effects of BHP on tumors were explored using reverse molecular docking. We also investigated the in vivo proapoptotic effect of BHP-NV in a nude mouse tumor model. RESULTS: NVs were successfully prepared with hydrated particle sizes ranging from 189.6 nm to 256.6 nm, spherical overall, and were able to remain stable in different media for 72 h with drug loading up to 15.2%. The NVs were be successfully internalized within 6 h with good biocompatibility. Neither BHP nor NV showed significant toxicity when administered alone, however, BHP-NV demonstrated significant side effects in vitro and in vivo. The apoptosis rate increased significantly from 14.13% to 66.34%. Experiments in vivo showed that BHP-NV exhibited significant apoptotic and tumor-suppressive effects. CONCLUSION: A targeted fluorescent NV with high drug delivery efficiency and sustained release protected the active center of BHP, constituting BHP-NV for targeted delivery. RPPMMRA demonstrated excellent biocompatibility, stability, and drug loading ability, whereas and BHP-NV demonstrated potent antitumor effects in vivo and in vitro.
format Online
Article
Text
id pubmed-10517702
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105177022023-09-24 Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy Zhang, Xi Zhang, Mingming Huang, Sijun Ohtani, Kiyoshi Xu, Li Guo, Yi Int J Nanomedicine Original Research OBJECTIVE: This study aimed to deliver a polypeptide from the Bax-BH3 domain (BHP) through the synthesis of self-assembled amphiphile nanovectors (NVs) and to assess their potential for cancer therapeutic applications and biological safety in vitro and in vivo. These findings provide valuable options for cancer intervention and a novel approach for the rational design of therapeutics. METHODS: We studied the antitumor activity of BHP by preparing RGDfK-PHPMA-b-Poly (MMA-alt-(Rhob-MA)) (RPPMMRA) and encapsulating it in BHP-NV. We also performed a series of characterizations and property analyses of RPPMMRA, including its size, stability, and drug-carrying capacity. The biocompatibility of RPPMMRA was evaluated in terms of cytotoxicity and hemolytic effects. The pro-apoptotic capacity of BHP was evaluated in vitro using mitochondrial membrane potential, flow cytometry, and apoptosis visualization techniques. The potential therapeutic effects of BHP on tumors were explored using reverse molecular docking. We also investigated the in vivo proapoptotic effect of BHP-NV in a nude mouse tumor model. RESULTS: NVs were successfully prepared with hydrated particle sizes ranging from 189.6 nm to 256.6 nm, spherical overall, and were able to remain stable in different media for 72 h with drug loading up to 15.2%. The NVs were be successfully internalized within 6 h with good biocompatibility. Neither BHP nor NV showed significant toxicity when administered alone, however, BHP-NV demonstrated significant side effects in vitro and in vivo. The apoptosis rate increased significantly from 14.13% to 66.34%. Experiments in vivo showed that BHP-NV exhibited significant apoptotic and tumor-suppressive effects. CONCLUSION: A targeted fluorescent NV with high drug delivery efficiency and sustained release protected the active center of BHP, constituting BHP-NV for targeted delivery. RPPMMRA demonstrated excellent biocompatibility, stability, and drug loading ability, whereas and BHP-NV demonstrated potent antitumor effects in vivo and in vitro. Dove 2023-09-19 /pmc/articles/PMC10517702/ /pubmed/37746048 http://dx.doi.org/10.2147/IJN.S427536 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Xi
Zhang, Mingming
Huang, Sijun
Ohtani, Kiyoshi
Xu, Li
Guo, Yi
Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title_full Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title_fullStr Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title_full_unstemmed Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title_short Engineered Polymeric Nanovector for Intracellular Peptide Delivery in Antitumor Therapy
title_sort engineered polymeric nanovector for intracellular peptide delivery in antitumor therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517702/
https://www.ncbi.nlm.nih.gov/pubmed/37746048
http://dx.doi.org/10.2147/IJN.S427536
work_keys_str_mv AT zhangxi engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy
AT zhangmingming engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy
AT huangsijun engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy
AT ohtanikiyoshi engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy
AT xuli engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy
AT guoyi engineeredpolymericnanovectorforintracellularpeptidedeliveryinantitumortherapy